News and Trends 23 Jun 2022 Scancell to produce and clinically validate T cell redirecting bispecific antibodies Scancell Holdings plc, which develops immunotherapies for the treatment of cancer and infectious disease, has announced it will develop its GlyMab antibodies into T cell redirecting bispecific (TCB) antibodies and take them into the clinic. The UK company said this is a promising new therapeutic approach to treat cancer. TCB antibodies have dual-binding specificity, which […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Krystal Biotech looks for FDA approval for dystrophic epidermolysis bullosa treatment U.S. gene therapy company Krystal Biotech, Inc, has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) for the treatment of patients with dystrophic epidermolysis bullosa (DEB). B-VEC is an investigational non-invasive, topical gene therapy designed to treat DEB at the molecular level by […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Gemelli Biotech to work on gastrointestinal diseases with new $19M funding U.S.-headquartered Gemelli Biotech Corp, which focuses on precision diagnostics for gastrointestinal (GI) diseases, has completed a $19 million series A finance round. Blue Ox Healthcare Partners, a private equity firm providing growth capital to companies targeting precision health and value-based care, led the investment round, joined by founding investor Cedars-Sinai, along with Carolina Angel Network, […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 BRIM Biotechnology enters OTC trading in Taiwan BRIM Biotechnology, Inc.has entered OTC (over the counter) trading in Taiwan. Established in July 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. The company’s current paid-in capital is approximately $23 million. BRIM has several novel drug products in its pipeline, all underpinned by […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Rensselaer researchers make face masks to fight viruses Researchers at Rensselaer Polytechnic Institute in Troy, NY, have developed N95 surgical face masks that are not just barriers to bacteria and viruses, but can also destroy them. The team said the antiviral, antibacterial masks can be worn for longer, creating less waste as the masks do not need to be replaced as frequently. Helen […] June 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Cystic fibrosis in the crosshairs as Carbon Biosciences launches with $38M funding Carbon Biosciences, a Longwood Fund founded biotech company developing parvovirus-derived gene therapies, has launched with $38 million of financing led by Agent Capital. Agent is joined by Longwood Fund, Astellas Venture Management LLC, the Cystic Fibrosis Foundation, Solasta Ventures, University of Tokyo Innovation Platform (UTokyoIPC), and Camford Capital. Massachusetts-based Carbon is harnessing novel parvovirus vectors […] June 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 From mugwort allergy to an effective vaccine? A research team at MedUni Vienna in Austria says it has discovered key mechanisms of allergy to pollen from the common weed mugwort, which could lay the foundation for the development of the world’s first vaccine. Mugwort (Artemisia vulgaris) poses a serious problem for some people with allergies in places where the plant is common […] June 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Galapagos to acquire CellPoint and AboundBio to advance cell therapies Belgian headquartered biotech Galapagos NV has acquired CellPoint and AboundBio, a move the Belgian company said propels it into next-generation cell therapy. Galapagos said the acquisitions give it access to an innovative, scalable, decentralized and automated point-of-care cell therapy supply model as well as a next-generation fully human antibody-based therapeutics platform. Galapagos said the goal […] June 22, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 Therorna funding to accelerate circRNA-based platform Therorna Inc., a Chinese biotech company specializing in the development of circular RNA (circRNA) technology-based new vaccines and therapies, including for COVID-19, has completed a $42 million series A financing round. The funding was co-led by MSA Capital, with participation from Sherpa Healthcare Partners, 3H Health Investment, and existing investors Quan Capital and Cenova Capital. […] June 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 Elypta raises $21M to develop early detection test for all cancers Elypta, a Swedish diagnostics company aiming to commercialize the first metabolism-based liquid biopsy for early detection of any cancer, has raised $21 million in a series A financing round led by Bonnier Ventures. “The series A is a pivotal moment for Elypta as it fully funds the development of our two leading indications,” said Karl […] June 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 Immuneel Therapeutics raises $15M and starts patient trials for CAR-T cancer therapies Indian biotech start-up Immuneel Therapeutics has announced it has started patient dosing in a CAR-T trial named “IMAGINE.” The Indian company focuses on creating access to Chimeric Antigen Receptor T cell therapy (CAR-T) and other cellular immunotherapies for the management and treatment of cancers. The phase II trial is the first industry sponsored CAR-T trial […] June 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 Biotalys and Novozymes partner on biofungicide Belgian agtech company Biotalys and Danish biotech company Novozymes have entered into a partnership to expand opportunities for Evoca, Biotalys’ first proprietary biocontrol product. Novozymes will explore additional routes for the upscaling and production of the bioactive protein of Evoca, with the option of a possible commercial collaboration for a future generation of the product. […] June 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email